Endophthalmitis After Intravitreal Injection of Antiangiogenic Agents or Corticosteroids, a Cohort Study of the French Population of Patients Who Received Injections Over 9 Years — ENIVAC

Intravitreal Injection Clinical Trial

Official title:
Endophthalmitis After Intravitreal Injection of Antiangiogenic Agents or Corticosteroids, a Cohort Study of the French Population of Patients Who Received Injections Over 9 Years

Status Completed

Clinical Trial Summary

Intravitreal injections (IVI) of antiangiogenic agents (AA) have revolutionized the management of age-related macular degeneration (AMD) and diabetic macular edema (DME) in particular. Approximately 600,000 AA IVIs are performed each year in France.

Corticosteroid IVIs are an alternative in the treatment of macular edema when it is diabetic or related to venous occlusion, but also due to inflammation.

Endophthalmitis is one of the most feared complications after IVI because of its poor prognosis, despite its low incidence (values found in the literature between 0.01% and 0.08%). IVI practices have evolved over the years based on the recommendations of specialized organizations, with the current recommendation not to use antibiotic prophylaxis.

The purpose of this study is to study the effect of intravitreal injections of anti-angiogenic agents and corticosteroids on the occurrence of endophthalmitis within 28 days following an injection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03635268
Study type	Observational
Source	Centre Hospitalier Universitaire Dijon
Contact
Status	Completed
Phase
Start date	January 1, 2016
Completion date	August 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05413330` - Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes.	Phase 2/Phase 3
Completed	`NCT04144985` - Comfort Comparison of Intravitreal Injection Eyelid Retraction Techniques	N/A
Completed	`NCT03732287` - Cooling Anesthesia for Intravitreal Injection	Phase 1/Phase 2
Completed	`NCT06130384` - Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.	Phase 4
Completed	`NCT05615805` - The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections	N/A
Withdrawn	`NCT04358471` - Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)	Phase 2
Completed	`NCT04827836` - Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection	N/A
Completed	`NCT03956797` - Long Term Safety of Cooling Anesthesia for Intravitreal Injection	N/A